Seres Therapeutics grants 6,500 stock options to director

Seres Therapeutics, Inc. director Stephen Berenson received a grant of stock options covering 6,500 shares of common stock at an exercise price of $7.14 per share.

Rhea-AI Filing Summary

Seres Therapeutics, Inc. director Stephen Berenson received a grant of stock options covering 6,500 shares of common stock at an exercise price of $7.14 per share. These options vest and become exercisable on the earlier of July 8, 2027 or the day immediately prior to the first annual meeting of stockholders occurring after July 8, 2026, and expire on July 7, 2036. Following this grant, he holds 6,500 derivative securities directly.

Insights

Equity Compensation Analyst

Routine director option grant with time- and meeting-based vesting.

Director Stephen Berenson was granted stock options for 6,500 shares of Seres Therapeutics common stock at an exercise price of $7.14 per share. This is characterized as a grant or award acquisition, typical for board compensation rather than an open-market purchase.

The options vest on the earlier of July 8, 2027 or the day immediately prior to the first annual meeting of stockholders after July 8, 2026, and expire on July 7, 2036. This structure aligns director incentives with longer-term company performance but does not by itself indicate a change in outlook, as it appears to be part of regular equity compensation.

Insider Trade Summary

Grant/Award: 6,500 shares

Grant/Award 1 txn

Insider Berenson Stephen

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy) F1	6,500	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 6,500 contracts (Direct)

Footnotes (1)

1. F1. The option vests and becomes exercisable on the earlier to occur of (i) July 8, 2027 or (ii) the day immediately prior to the first annual meeting of the Company's stockholders occurring after July 8, 2026.

Key Figures

Option Shares Granted: 6,500 shares Exercise Price: $7.14 per share Shares Following Transaction: 6,500 derivative securities +2 more

5 metrics

Option Shares Granted 6,500 shares Stock option grant to director Stephen Berenson

Exercise Price $7.14 per share Strike price of stock options granted

Shares Following Transaction 6,500 derivative securities Total options held directly after the grant

Expiration Date July 7, 2036 Expiration of stock options granted

Latest Vesting Date July 8, 2027 Latest date options vest, subject to earlier annual meeting trigger

Key Terms

Stock Option (right to buy), exercise price, vests and becomes exercisable, annual meeting of the Company's stockholders

4 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

exercise price financial

"conversion_or_exercise_price: 7.1400"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vests and becomes exercisable financial

"The option vests and becomes exercisable on the earlier to occur"

annual meeting of the Company's stockholders financial

"the first annual meeting of the Company's stockholders occurring after"

FAQ

What did MCRB director Stephen Berenson receive in this Form 4 filing?

Director Stephen Berenson received a grant of stock options covering 6,500 shares of Seres Therapeutics common stock at an exercise price of $7.14 per share as equity compensation.

What is the exercise price of the stock options granted to Stephen Berenson at Seres Therapeutics (MCRB)?

The stock options granted to Stephen Berenson have an exercise price of $7.14 per share, meaning he can buy Seres Therapeutics common stock at that fixed price once vested.

When do Stephen Berenson’s Seres Therapeutics (MCRB) stock options vest?

The options vest on the earlier of July 8, 2027 or the day immediately prior to the first annual meeting of stockholders occurring after July 8, 2026, subject to continued service terms.

What is the expiration date of the stock options granted to Stephen Berenson at MCRB?

The granted stock options expire on July 7, 2036. After this date, any unexercised portion of the 6,500-share option award can no longer be exercised for Seres Therapeutics stock.

How many Seres Therapeutics (MCRB) derivative securities does Stephen Berenson hold after this transaction?

Following this option grant, Stephen Berenson holds 6,500 derivative securities (stock options) directly, each representing the right to acquire one share of Seres Therapeutics common stock upon exercise.

Is the Form 4 transaction for MCRB an open-market buy or a compensation grant?

The Form 4 reports a grant or award acquisition of stock options to director Stephen Berenson, classified as equity compensation rather than an open-market purchase or sale of MCRB shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/10/2026 - 04:15 PM Accepted by SEC EDGAR 07/10/2026 - 04:15 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Berenson Stephen

(Last) (First) (Middle)

C/O SERES THERAPEUTICS, INC.

101 CAMBRIDGE PARK DRIVE

(Street)

CAMBRIDGE MASSACHUSETTS 02140

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Seres Therapeutics, Inc. [ MCRB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$7.14	07/08/2026		A		6,500		(1)	07/07/2036	Common Stock	6,500	$0	6,500	D

Explanation of Responses:

1. The option vests and becomes exercisable on the earlier to occur of (i) July 8, 2027 or (ii) the day immediately prior to the first annual meeting of the Company's stockholders occurring after July 8, 2026.

	/s/ Thomas J. DesRosier, Attorney-in-Fact	07/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)